Hyaluronic acid
(Synonyms: 玻尿酸; Hyaluronan; Hyaluronate) 目录号 : GC32732
透明质酸 (HA) 是由双糖的重复单元组成的生物聚合物，其中包括通过 β- (1 4) 和 β- (1 3) 糖苷连接的 D- 葡萄糖醛酸分子和 N- 乙酰氨基葡萄糖分子。
Cas No.:9004-61-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
The human pancreatic carcinoma cell line MIA PaCa-2 |
|
Preparation Method |
MIA PaCa-2 cellsincubated with 10 µm MG132. The cells were then incubated with Hyaluronic acid for 1 h or with 100 ng/ml PMA for 30 min at 37 °C in the presence of 10 µm MG132, and the culture supernatants were collected for analysis by enzyme-linked immunosorbent assay (ELISA). |
|
Reaction Conditions |
5-100ug/ml Hyaluronic acid for 1 h |
|
Applications |
Hyaluronic acid oligosaccharides of a specific size range induce CD44 cleavage from tumor cells. |
| Animal experiment [2]: | |
|
Animal models |
Male nude mice, 6 to 8 weeks old and weighing 22 to 28 g |
|
Preparation Method |
The back of each mouse was divided into 4 regions that randomly received different treatments: no treatment, 0.30 mL Biohyalux ( Hyaluronic acid group), 0.30 mL fat (FAT group), and lumps formed by serial injection of 0.30 mL Biohyalux and 0.30 mL fat ( Hyaluronic acid /FAT group) |
|
Dosage form |
0.30 mL Hyaluronic acid |
|
Applications |
The expression levels of CD31 and vascular endothelial growth factor (VEGF) in the Hyaluronic acid/FAT group were higher than those in the FAT group, but the difference was only significant for VEGF expression. |
|
References: [1]. Sugahara KN, Murai T,et,al. Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem. 2003 Aug 22;278(34):32259-65. doi: 10.1074/jbc.M300347200. Epub 2003 Jun 11. PMID: 12801931. |
|
Hyaluronic acid (HA) is a biopolymer composed of repeating units of disaccharides, which include molecules of D-glucuronic acid and N-acetylglucosamine molecules linked by β- (1 4) and β- (1 3)glycosides. It belongs to a group of substances called mucopolysaccharides belonging to the glycosaminoglycans (GAGs) family[1]. Hyaluronic acid also plays an important role in wound healing, ovulation, fertilization, signal transduction, and tumor physiology[2,3].
Hyaluronic acid oligosaccharides of a specific size range induce CD44 cleavage from tumor cells. It raise the possibility that small Hyaluronic acid oligosaccharides, which are known to occur in various tumor tissues, promote tumor invasion by enhancing the tumor cell motility that may be driven by CD44 cleavage[4]. Hyaluronic acid enhances tumor cell adhesion and migration and activates the Ras-mitogen-activated protein kinase pathway as well as the phosphoinositide 3-kinase pathway[5]. Purified autologous adipose-derived stem cells (ADSCs) combined with Hyaluronic acid facilitated adipose tissue regeneration in a rabbit subcutaneous model[7].
In mice, Cross-linked Hyaluronic acid had minimal effect on the early retention rate of surrounding fat grafts, but enhanced their vascularization. Fat grafts should be not injected into lumps of cross-linked HA. Therefore, agglomerated cross-linked Hyaluronic acid should be dissolved before fat transplantation[6]. Hyaluronic acid-NP treatment of diet-induced obese (DIO) mice reduced the epididymal fat mass and suppressed the induction of adipogenic and lipogenic regulators, while these effects were attenuated in the CD44-null mice[8]. In the animal study, the mice were fed a high-fat diet and treated with Clenbuterol by oral administration, or injected with Clenbuterol-modified Hyaluronic acid hydrogel (HAC) regularly. Both groups showed reduction in whole-body, visceral, and gonadal fat contents and body weight. The abdominal fat was analyzed using MRI imaging in adipose mode and water mode. The abdominal fat ratio in the mice treated with normal diet and those given intra-adipose injections with HAC had the lowest value among the test groups[9].
References:
[1]. Salwowska NM, Bebenek KA, et,al.Physiochemical properties and application of hyaluronic acid: a systematic review. J Cosmet Dermatol. 2016 Dec;15(4):520-526. doi: 10.1111/jocd.12237. Epub 2016 Jun 21. PMID: 27324942.
[2]. HAMERMAN D, SCHUSTER H. Hyaluronate in normal human synovial fluid. J Clin Invest. 1958 Jan;37(1):57-64. doi: 10.1172/JCI103585. PMID: 13491713; PMCID: PMC293057.
[3]. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004 Jul;4(7):528-39. doi: 10.1038/nrc1391. PMID: 15229478.
[4]. Sugahara KN, Murai T, et,al. Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem. 2003 Aug 22;278(34):32259-65. doi: 10.1074/jbc.M300347200. Epub 2003 Jun 11. PMID: 12801931.
[5]. Sohara Y, Ishiguro N, et,al. Hyaluronan activates cell motility of v-Src-transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide 3-kinase-Akt in a tumor-specific manner. Mol Biol Cell. 2001 Jun;12(6):1859-68. doi: 10.1091/mbc.12.6.1859. PMID: 11408591; PMCID: PMC37347.
[6]. Zheng Z, Lei X, et,al.Changes in Human Fat Injected Alongside Hyaluronic Acid in the Backs of Nude Mice. Aesthet Surg J. 2021 May 18;41(6):NP631-NP642. doi: 10.1093/asj/sjaa351. PMID: 33326559.
[7]. Piccinno MS, Veronesi E, et,al. Adipose stromal/stem cells assist fat transplantation reducing necrosis and increasing graft performance. Apoptosis. 2013 Oct;18(10):1274-89. doi: 10.1007/s10495-013-0878-7. PMID: 23828239; PMCID: PMC3775159.
[8]. Lee WH, Rho JG, et,al.Self-assembled hyaluronic acid nanoparticle suppresses fat accumulation via CD44 in diet-induced obese mice. Carbohydr Polym. 2020 Jun 1;237:116161. doi: 10.1016/j.carbpol.2020.116161. Epub 2020 Mar 18. PMID: 32241446.
[9]. Chen WY, Lin FH. Oxidized Hyaluronic Acid Hydrogels as a Carrier for Constant-Release Clenbuterol Against High-Fat Diet-Induced Obesity in Mice. Front Endocrinol (Lausanne). 2021 Mar 12;12:572690. doi: 10.3389/fendo.2021.572690. PMID: 33776904; PMCID: PMC7996091.
透明质酸 (HA) 是由双糖的重复单元组成的生物聚合物，其中包括通过 β- (1 4) 和 β- (1 3) 糖苷连接的 D- 葡萄糖醛酸分子和 N- 乙酰氨基葡萄糖分子。它属于一组称为粘多糖的物质，属于糖胺聚糖 (GAG) 家族[1]。透明质酸还在伤口愈合、排卵、受精、信号转导和肿瘤生理学中发挥重要作用[2,3]。
特定大小范围的透明质酸寡糖诱导肿瘤细胞中的 CD44 裂解。它提出了一种可能性，即已知存在于各种肿瘤组织中的小透明质酸寡糖通过增强可能由 CD44 切割驱动的肿瘤细胞运动来促进肿瘤侵袭[4]。透明质酸可增强肿瘤细胞粘附和迁移，并激活 Ras-mitogen-activated protein kinase 通路以及磷酸肌醇 3-kinase 通路[5]。纯化的自体脂肪干细胞 (ADSCs) 结合透明质酸促进兔皮下模型的脂肪组织再生[7]。
在小鼠体内，交联透明质酸对周围脂肪移植物的早期保留率影响很小，但增强了它们的血管形成。不应将脂肪移植物注射到交联 HA 块中。因此，在脂肪移植前应溶解结块的交联透明质酸[6]。透明质酸-NP 治疗饮食诱导的肥胖 (DIO) 小鼠可减少附睾脂肪量并抑制脂肪生成和脂肪生成调节剂的诱导，而这些作用在 CD44 缺失小鼠中减弱 [8]。在动物研究中，小鼠被喂食高脂肪饮食，并通过口服克伦特罗治疗，或定期注射克仑特罗修饰的透明质酸水凝胶 (HAC)。两组均显示全身、内脏和性腺脂肪含量和体重都有所下降。使用脂肪模式和水模式下的 MRI 成像分析腹部脂肪。正常饮食组和脂肪内注射HAC组的小鼠腹脂率在各试验组中最低[9]。
| Cas No. | 9004-61-9 | SDF | |
| 别名 | 玻尿酸; Hyaluronan; Hyaluronate | ||
| Canonical SMILES | O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](OC)[C@@H](C(O)=O)O2)[C@@H](NC(C)=O)[C@H](C)O[C@@H]1CO.[n] | ||
| 分子式 | (C14H21NO11)n | 分子量 | 379.32(monomer) |
| 溶解度 | Water : 6.8 mg/mL | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6363 mL | 13.1815 mL | 26.363 mL |
| 5 mM | 0.5273 mL | 2.6363 mL | 5.2726 mL |
| 10 mM | 0.2636 mL | 1.3181 mL | 2.6363 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Hyaluronic acid and wound healing
J Pharm Pharm Sci 2015;18(1):53-60.PMID:25877441DOI:10.18433/j3k89d.
Background: We developed an experimental model of ethanol-induced dermatotoxicity and hepatocytoxicity using normal human keratinocytes and normal human hepatocytes that preserve inducible cytochrome p450 activities. The original work was described in several articles. The objective of this study was to determine whether Hyaluronic acid attenuates skin necrosis, and to further clarify its uses in wound repair in humans, animal models and in vitro studies. Methods: We performed a systematic review of the literature using the terms "Hyaluronic acid" and "wound healing". PubMed was searched for studies published during the period 2010-2014. Results: Hyaluronic acid is used in tissue regeneration alone or in combination with herbal or Western medicine. Scaffolds made up of Hyaluronic acid were used to embed basic fibroblast growth factor. Conclusion: Hyaluronic acid extracts are safe and efficacious products to be used in skin repair.
Hyaluronic acid fillers: history and overview
Facial Plast Surg 2011 Dec;27(6):523-8.PMID:22205525DOI:10.1055/s-0031-1298785.
Hyaluronic acid (HA) fillers have many favorable characteristics that make it a popular injectable filler device. Its minimal immunogenicity and relative ease of use has helped HA become the most commonly used injectable filler today. A brief history of injectable fillers, the various injection techniques, and legal ramifications are discussed. A review of the most recent literature compares the efficacy and safety of HA to other injectable filler substances.
Hyaluronic acid-Based wound dressings: A review
Carbohydr Polym 2020 Aug 1;241:116364.PMID:32507198DOI:10.1016/j.carbpol.2020.116364.
Hyaluronic acid (HA), a non-sulfated glycosaminoglycan (GAG), is a major component of skin extracellular matrix (ECM) and it is involved in the inflammatory response, angiogenesis, and tissue regeneration process. Due to the intrinsic properties of HA (such as biocompatibility, biodegradability and hydrophilic character), it has been used to produce different wound dressings, namely sponges, films, hydrogels, and electrospun membranes. Herein, an overview of the different HA-based wound dressings that have been produced so far is provided as well as the future directions regarding the strategies aimed to improve the mechanical stability of HA-based wound dressings, along with the incorporation of biomolecules intended to ameliorate their biological performance during the healing process.
Hyaluronic acid
Adv Exp Med Biol 2018;1059:137-153.PMID:29736572DOI:10.1007/978-3-319-76735-2_6.
In recent times, the field of tissue engineering and regenerative medicine (TERM) has considerably increased the extent of therapeutic strategies for clinical application in orthopedics. However, TERM approaches have its rules and requirements, in the respect of the biologic response of each tissue and bioactive agents which need to be considered, respected, and subject of ongoing studies. Different medical devices/products have been prematurely available on the market and used in clinics with limited success. However, other therapeutics, when used in a serious and evidence-based approach, have achieved considerable success, considering the respect for solid expectations from doctors and patients (when properly informed).Orthobiologics has appeared as a recent technological trend in orthopedics. This includes the improvement or regeneration of different musculoskeletal tissues by means of using biomaterials (e.g., Hyaluronic acid), stem cells, and growth factors (e.g., platelet-rich plasma). The potential symbiotic relationship between biologic therapies and surgery makes these strategies suitable to be used in one single intervention.However, herein, the recent clinical studies using Hyaluronic acid (HA) in the treatment of orthopedic conditions will mainly be overviewed (e.g., osteochondral lesions, tendinopathies). The possibilities to combine different orthobiologic agents as TERM clinical strategies for treatment of orthopedic problems will also be briefly discussed.
Periocular Hyaluronic acid fillers: applications, implications, complications
Curr Opin Ophthalmol 2019 Sep;30(5):395-400.PMID:31261189DOI:10.1097/ICU.0000000000000595.
Purpose of review: The use of dermal filler in the periocular area is increasing - both for functional and aesthetic indications. Hyaluronic acid fillers dominate the market; these treatments offer an alternative to some surgical procedures with the advantage of instant results, minimal healing time and low complication rates. However, success depends on judicious selection of patients, products and procedures to achieve favourable outcomes. This article reviews current understanding of the principal complications in the periocular area and their management. Recent findings: Hyaluronic acid is a ubiquitous, biodegradable, nonspecies-specific molecular substrate with limited potential for immunogenic reactions. However, in the periocular area, such products can migrate and last significantly longer than the expected filler lifespan. Contamination or subsequent immune stimulation can trigger delayed-onset inflammatory reactions. Though minor vascular occlusions are not uncommon, cases of blindness secondary to facial filler injections are thought to be rare. Timely enzymatic degradation with injectable hyaluronidase can be effective in the treatment of some such complications. But recent studies demonstrate lack of penetration through arterial walls and optic nerve sheath, casting doubt on the role of retrobulbar hyaluronidase in the management of vision loss because of embolism with Hyaluronic acid filler. Summary: Hyaluronic acid fillers represent an emerging and important addition to the armamentarium of the oculofacial plastic surgeon with their use in the aesthetic field also expected continue to rise. The oculoplastic facial surgeon, armed with a thorough knowledge of facial anatomy, safe injection planes and the means of minimizing and treating complications is in the best position to lead clinically in the use of this well tolerated and effective treatment modality.